Evidence map›Paper›PMID 40938504›Full record

Trial reportChinese journal of integrative medicine2026

Effect of Huashi Tongbi Formula on Erectile Dysfunction with Damp Heat Affecting Pi (Spleen) Pattern: A Multicentre, Randomized, Controlled Noninferiority Trial.

He-de Zou, Pei-Hai Zhang, Wen-Kang Chen, Bao-Feng Hu, Jian-Wei Wang, Hong-Sen Zeng, Guan-Chao Du, Qing-He Gao, Zi-Yang Ma, Yong-Jie Ma and 6 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

He-de Zou *Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Pei-Hai Zhang *Department of Andrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
Wen-Kang ChenInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Bao-Feng HuDepartment of Nephropathy, Qian'an Traditional Chinese Medicine Hospital, Tangshan, 064404, China.
Jian-Wei WangDepartment of Nephropathy, Qian'an Traditional Chinese Medicine Hospital, Tangshan, 064404, China.
Hong-Sen ZengDepartment of Andrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
Guan-Chao DuDepartment of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Qing-He GaoDepartment of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Zi-Yang MaDepartment of Andrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
Yong-Jie MaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Ya-Peng ZhangInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Rui CaoInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
He-Kun ZhangInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Wei LinInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Hao-Ran XuInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Jia-You ZhaoInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China. zhaojiayou520@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect and safety of Chinese herbal compound Huashi Tongbi Formula (HTF) for the treatment of erectile dysfunction (ED) with damp heat affecting Pi (Spleen) pattern, and explore the possible mechanisms based on the analysis of gut microbiota.

methodsIn this multicentre, randomized, parallel, positive control, noninferiority trial, a total of 162 ED patients with damp heat affecting Pi pattern were randomly divided into a treatment group (108 patients) and a control group (54 patients) in a 2:1 ratio using a random number table method. The treatment group was administered HTF granules (1 bag each time, twice a day). The control group was given sildenafil citrate tablets (50 mg, orally as needed). Both groups were treated for 8 weeks with a 8-week followed-up period. The main indicator was effective rate after 8-week treatment analysed using intention-to-treat (ITT) and per-protocol (PP) methods, and the secondary indicators included International Index of Erectile Function-5 (IIEF-5) score, Erectile Quality Score (EQS), and Chinese medicine syndrome (CMS) score, which were analysed using ITT every 2 weeks during 8-week treatment period, and every 4 weeks during 8-week follow-up period. The 16S rDNA sequencing was used to analyse the impact of HTF on the gut microbiota. The adverse events (AEs) and changes in safety indicators of the two groups were recorded.

resultsA total of 162 patients were included in the ITT analysis, with 23 patients dropping out during the trial period (12 in the treatment group and 11 in the control group), and 139 patients were included in the PP analysis. ITT and PP analyses revealed that after 8-week treatment the difference and 95% confidence intervals (CIs) in the effective rates between the treatment and the control groups were -3.7% (-17.9%, 10.5%) and -4.5% (-18.2%, 9.2%), respectively. At 2 weeks of treatment, the treatment group showed lower IIEF-5 and EQS scores but higher CMS score vs. control (P<0.05); at 4 weeks, IIEF-5 remained lower (P<0.05), while EQS and CMS scores were comparable (P>0.05); by 6 weeks, all scores (IIEF-5, EQS, CMS) were similar between groups (P>0.05); at 8 weeks, IIEF-5 and EQS were comparable, but CMS scores were lower (P<0.05). During 4- and 8-week follow-up, the treatment group had higher IIEF-5 and EQS scores and lower CMS scores (P<0.05). Both groups showed significant improvements in all scores from baseline (P<0.05). There was no significant difference in the safety indicators between groups (P>0.05). After HTF treatment, the relative abundances of Lachnospiraceae and Blautia increased, contributing the most to the differences in the microbial communities between groups. The abundances of Levilactobacillus and Lactiplantibacillus increased, whereas the abundances of Bilophila, Saccharimonadia, Patescibacteria, and others decreased in the treatment group (linear discriminant analysis score>2). Nine predictive functions of the gut microbiota including amino acid related enzymes, exosome, mitochondrial biogenesis, etc. were reduced, whereas protein kinase function increased in the treatment group (P<0.05).

conclusionHTF showed noninferior efficacy to sildenafil for ED with damp heat affecting Pi pattern, with the advantages of relieving overall symptoms and stable and lasting therapeutic effect after discontinuation, potentially mediated by gut microbiota modulation. (Registration No. ChiCTR2300067825).

Indexed as

Drugs, Chinese HerbalErectile DysfunctionHot TemperatureAdultGastrointestinal MicrobiomeHumansMaleMiddle AgedTreatment OutcomeDrugs, Chinese HerbalChinese medicineerectile dysfunctiongut microbiotaHuashi Tongbi Formulanoninferiorityrandomized controlled trials

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.